p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas

Susan J. Pacinda, Suzanne C. Ledet, Margaret M. Gondo, Claire Langston, Richard W. Brown, Pedro A. Carmona, Raymond B. Franklin, Victor L. Roggli, Philip T. Cagle

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Pulmonary blastomas (PBs) are rare primary malignancies that include adult types: biphasic pulmonary blastoma (BPB) and well-differentiated fetal adenocarcinoma (WDFA); and childhood type: pleuropulmonary blastoma (PPB). Their pathogenesis and relationship to bronchogenic carcinoma (BCA) are controversial. To determine whether or not PB share molecular pathological features with BCA, the authors immunostained three BPB, three WDFA, three PPB, and 80 standard BCA for p53 protein and MDM2 protein, gene products believed to be significant in die pathogenesis of BCA. Paraffin-embedded tissue sections were immunostained with monoclonal antibody to p53 and MDM2 proteins. Strong intranuclear staining in greater than 10% of cells was considered positive. Three (50%) BPB and WDFA stained for p53 and five (83%) for MDM2. None of the PPB stained for p53, and one PPB did not stain for either p53 or MDM2. Five of six adult type PB occurred in smokers, whereas none of die PPB was associated with smoking. Seventy-five (94%) of the BCA stained for MDM2 and 46 (61%) for p53. Immunostaining patterns for p53 and MDM2 in adult types of PB, and not PPB, appear similar to those for BCA. This may suggest that adult type PB, but not childhood PB, have a similar pathogenesis to BCA.

Original languageEnglish (US)
Pages (from-to)542-546
Number of pages5
JournalHuman Pathology
Volume27
Issue number6
DOIs
StatePublished - 1996
Externally publishedYes

Keywords

  • immunohistochemistry
  • lung carcinoma
  • murine double-minute-2
  • p53
  • pulmonary blastoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas'. Together they form a unique fingerprint.

Cite this